The aim of this study has been to evaluate the efficacy of the IL-5 receptor blocker benralizumab on chronic rhinosinusitis with nasal polyposis (CRSwNP), associated with severe eosinophilic allergic asthma. Ten patients with severe eosinophilic allergic asthma and CRSwNP were enrolled. Sino-nasal outcome test (SNOT-22), numerical rating scale (NRS), endoscopic nasal polyp score, Lund Mackey CT (computed tomography) score, and blood eosinophil count were measured at baseline and after 24 weeks of treatment with benralizumab. All the above clinical, endoscopic, imaging, and hematological parameters significantly improved after 24 weeks of treatment with benralizumab. In particular, SNOT-22 decreased from 61.10 ± 17.20 to 26.30 ± 19.74 (P < 0.001), NRS decreased from 7.20 ± 1.55 to 3.40 ± 2.22 (P < 0.001), the endoscopic polyp nasal score decreased from 4.20 ± 1.32 to 2.50 ± 1.78 (P < 0.001), the Lund-Mackay CT score decreased from 16.60 ± 5.50 to 6.90 ± 5.99 (P < 0.001), and blood eosinophil count decreased from 807.3 ± 271.1 cells/μL to 0 cells/μL (P < 0.0001). These results strongly suggest that benralizumab exerted a very effective therapeutic action on CRSwNP associated with severe asthma, thus improving nasal symptoms and decreasing polyp size.

这项研究的目的是评估IL-5受体阻滞剂贝那利珠单抗对伴有严重嗜酸性粒细胞变应性哮喘的慢性鼻-鼻窦炎伴鼻息肉病（CRSwNP）的疗效。招募了10例严重嗜酸性粒细胞过敏性哮喘和CRSwNP患者。在基线和贝那利珠单抗治疗24周后，测量了鼻中转归试验（SNOT-22），数字量表（NRS），鼻内镜鼻息肉评分，Lund Mackey CT（计算机断层扫描）评分和嗜酸性粒细胞计数。用贝那利珠单抗治疗24周后，上述所有临床，内镜，影像学和血液学参数均得到明显改善。尤其是SNOT-22从61.10±17.20降至26.30±19.74（P <0.001），NRS从7.20±1.55降至3.40±2.22（P<0.001），内窥镜鼻息肉评分从4.20±1.32降低到2.50±1.78（P <0.001），Lund-Mackay CT评分从16.60±5.50降低到6.90±5.99（P <0.001），血液嗜酸性粒细胞计数降低从807.3±271.1细胞/μL到0细胞/μL（P <0.0001）。这些结果强烈表明，贝那利珠单抗对与严重哮喘相关的CRSwNP发挥了非常有效的治疗作用，从而改善了鼻部症状并减小了息肉大小。